Tyrosine Kinase
Tyrosine Kinase(酪氨酸激酶)
- Bcr-Abl(73)
- Ack1(3)
- Axl(6)
- ALK(64)
- BMX Kinase(3)
- Broad Spectrum Protein Kinase Inhibitor(10)
- c-FMS(42)
- c-Kit(58)
- c-MET(99)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(278)
- EphB4(1)
- FAK(39)
- FGFR(104)
- FLT3(97)
- HER2(15)
- IGF1R(34)
- Insulin Receptor(46)
- IRAK(32)
- ITK(10)
- Lck(1)
- LRRK2(25)
- PDGFR(113)
- PTKs/RTKs(10)
- Pyk2(8)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(33)
- Src(108)
- Tie-2 (4)
- Trk(43)
- VEGFR(200)
- Kinase
- Discoidin Domain Receptor(16)
- DYRK(35)
- Ephrin Receptor(13)
- RET(30)
- ROS(14)
- TAM Receptor(33)
- IGFBR(1)
- Others(55)
Tyrosine Kinase 相关产品(1402)
- GC14476EntrectinibCAS: 1108743-60-7纯度: >99.00%
Entrectinib是一种具有口服活性、可穿透血脑屏障（BBB）且在中枢神经系统起作用的TrkA/B/C、ROS1与ALK抑制剂，其IC 50 值分别为1、3、5、12和7nM。
- GC14794PF-06463922CAS: 1454846-35-5纯度: >99.50%
PF-06463922是一种新型的、具有口服活性的ALK（IC 50 =15-113nM）和ROS1（K i s=0.025-0.7nM）双重抑制剂。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC14136 | BMS 599626 dihydrochloride | 1781932-33-9 | - | |
EGFR and ErbB2 inhibitor,potent and selective | ||||
| GC14218 | TP-0903 | 1341200-45-0 | >99.50% | |
An Axl kinase inhibitor | ||||
| GC14237 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | >99.50% | |
A Bcr-Abl inhibitor | ||||
| GC14241 | LDC1267 | 1361030-48-9 | >98.00% | |
A TAM family kinase inhibitor | ||||
| GC14259 | HKI 357 | 848133-17-5 | >99.00% | |
An irreversible dual inhibitor of EGFR and HER2 | ||||
| GC14284 | SR 2211 | 1359164-11-6 | >98.50% | |
Selective inverse agonist of RORγ | ||||
| GC14292 | Apatinib Mesylate | 811803-05-1 | >98.00% | |
A selective VEGFR2 inhibitor | ||||
| GC14295 | Gefitinib hydrochloride | 184475-55-6 | >99.00% | |
An EGFR inhibitor | ||||
| GC14349 | SB525334 | 356559-20-1 | >99.50% / >98.00% | |
SB525334已被鉴定为一种高效且选择性的转化生长因子β1（TGF-β1）受体、活化素受体样激酶（ALK5）抑制剂。SB525334对ALK5激酶活性的IC 50 为14.3nM。 | ||||
| GC14418 | SR 1555 (hydrochloride) | 2309312-90-9 | - | |
inverse agonist of RORγ | ||||
| GC14446 | ASP3026 | 1097917-15-1 | >99.50% | |
An ALK inhibitor | ||||
| GC14476 | Entrectinib | 1108743-60-7 | >99.00% | |
Entrectinib是一种具有口服活性、可穿透血脑屏障（BBB）且在中枢神经系统起作用的TrkA/B/C、ROS1与ALK抑制剂，其IC 50 值分别为1、3、5、12和7nM。 | ||||
| GC14488 | NPS-1034 | 1221713-92-3 | >98.00% | |
A dual MET/AXL inhibitor | ||||
| GC14494 | AG 99 | 122520-85-8 | >99.00% | |
An inhibitor of EGF receptor kinase | ||||
| GC14544 | JNJ-10198409 | 627518-40-5 | >97.00% | |
A potent PDGF tyrosine kinase inhibitor | ||||
| GC14582 | SU5614 | 1055412-47-9 | - | |
A multi-kinase inhibitor | ||||
| GC14650 | CGP60474 | 164658-13-3 | >98.50% | |
A CDK inhibitor | ||||
| GC14654 | HNGF6A | 1093111-54-6 | - | |
HNGF6A是一种人工合成的多肽，属于人类素（Humanin）类似物。 | ||||
| GC14676 | Pacritinib (SB1518) | 937272-79-2 | - | |
An equipotent inhibitor of FLT3 and JAK2 | ||||
| GC14767 | PF-00562271 | 939791-38-5 | >99.00% | |
A selective FAK/PYK2 inhibitor | ||||
| GC14779 | RR-src | 81156-93-6 | - | |
A synthetic peptide substrate | ||||
| GC14794 | PF-06463922 | 1454846-35-5 | >99.50% | |
PF-06463922是一种新型的、具有口服活性的ALK（IC 50 =15-113nM）和ROS1（K i s=0.025-0.7nM）双重抑制剂。 | ||||
| GC14856 | EGFR/ErbB2 Inhibitor | 179248-61-4 | >99.50% | |
A dual inhibitor of EGFR and ErbB2 | ||||
| GC14890 | AG-183 | 122520-90-5 | >98.00% | |
An inhibitor of EGF receptor kinase | ||||